Oseltamivir, one of the new neuraminidase inhibitors, appears to be a safe and effective therapy for the prevention and treatment of influenza. The primary disadvantages to its use are the need to initiate treatment within 2 days of the onset of symptoms and cost. The recent FDA approval of this agent for use in children and the availability of an oral liquid dosage formulation will likely result in a significant change in the management of influenza in the pediatric population.
Pediatr Pharm. 2001;7(2) © 2001 Children's Medical Center, University of Virginia
Cite this: Oseltamivir: A New Option for the Management of Influenza in Children - Medscape - Feb 01, 2001.